PFE
PfizerDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The post-earnings bull read is that Pfizer delivered a clean Q1 beat/reaffirmation, showed 7% operational growth excluding COVID products, and is getting visible help from newer and acquired brands, which supports the deterministic positive prior if execution continues.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
COVID product erosion remains large, with Comirnaty down 59% operationally and Paxlovid down 63% operationally in Q1 2026.
Momentum
14
Value
58
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.75 · Bull $30.50 · Bear $22.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $28.38
Why
Momentum14 · Δ7d +8.4
Value58 · Δ7d -0.3
Sentiment55 · Δ7d -7.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
14
26% active weight
Current posture
7d trendImproving
Δ7d
+8.4
Δ21d
-5.0
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.1
Sentiment
55
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-4.3
Why this grade
Composite grade D. Momentum 13.6 / Value 57.7 / Sentiment 54.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$142.77B
Beta
0.43
Shares Out
5.7B
P/E (TTM)
14.7
P/S (TTM)
2.28
P/FCF (TTM)
213.60
Rev YoY
+5.4%
EPS YoY
-9.8%
Gross Margin
+65.2%
Op Margin
+16.5%
Net Debt
$53.82B
Current Ratio
1.25
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology